What is HC Wainwright's Estimate for ASND FY2026 Earnings?

Key Points

• HC Wainwright raised its FY2026 EPS estimate for Ascendis Pharma to $3.93 from $3.85, above the current consensus estimate of $3.69. The firm forecasts FY2027 EPS of $11.30.
• Ascendis Pharma reported quarterly EPS of $1.03, missing the $1.71 analyst consensus, while revenue of $387.22 million exceeded estimates of $376.75 million.
• Analyst sentiment remains favorable, with the stock carrying a consensus “Buy” rating and an average price target of $310, compared with shares recently opening at $263.52.

Ascendis Pharma A/S (NASDAQ:ASND - Free Report) - Equities researchers at HC Wainwright lifted their FY2026 EPS estimates for Ascendis Pharma A/S in a research note issued to investors on Thursday, September 10th. HC Wainwright analyst M. Kapoor now forecasts that the biotechnology company will post earnings per share of $3.93 for the year, up from their previous estimate of $3.85. The consensus estimate for Ascendis Pharma A/S's current full-year earnings is $3.69 per share. HC Wainwright also issued estimates for Ascendis Pharma A/S's Q2 2027 earnings at $2.35 EPS, Q3 2027 earnings at $3.05 EPS, Q4 2027 earnings at $4.25 EPS and FY2027 earnings at $11.30 EPS.

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) last released its quarterly earnings results on Friday, August 14th. The biotechnology company reported $1.03 earnings per share for the quarter, missing analysts' consensus estimates of $1.71 by ($0.68). The business had revenue of $387.22 million during the quarter, compared to analyst estimates of $376.75 million. Ascendis Pharma A/S had a net margin of 70.99% and a return on equity of 32.54%.

A number of other analysts also recently weighed in on the company. Barclays cut their target price on Ascendis Pharma A/S from $345.00 to $329.00 and set an "overweight" rating for the company in a research report on Friday, August 14th. Wedbush restated an "outperform" rating and issued a $327.00 price target on shares of Ascendis Pharma A/S in a research report on Tuesday, September 1st. Wall Street Zen raised Ascendis Pharma A/S from a "hold" rating to a "buy" rating in a research note on Saturday, August 15th. Citigroup initiated coverage on shares of Ascendis Pharma A/S in a research report on Monday, May 18th. They set a "buy" rating and a $355.00 price objective for the company. Finally, Stifel Nicolaus reduced their price objective on shares of Ascendis Pharma A/S from $328.00 to $326.00 and set a "buy" rating on the stock in a research note on Monday, August 31st. Two research analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and one has issued a Hold rating to the stock. According to MarketBeat.com, Ascendis Pharma A/S has a consensus rating of "Buy" and an average target price of $310.00.

Ascendis Pharma A/S Stock Performance

Shares of NASDAQ:ASND opened at $263.52 on Monday. The business's 50 day simple moving average is $257.42 and its 200 day simple moving average is $242.17. Ascendis Pharma A/S has a 1 year low of $186.05 and a 1 year high of $282.15. The company has a debt-to-equity ratio of 0.27, a current ratio of 2.99 and a quick ratio of 2.32. The company has a market capitalization of $16.44 billion, a P/E ratio of 20.44 and a beta of 0.35.

Insider Buying and Selling at Ascendis Pharma A/S

In other Ascendis Pharma A/S news, Director Jean-Jacques Bienaimé bought 2,000 shares of Ascendis Pharma A/S stock in a transaction on Friday, August 14th. The shares were purchased at an average price of $246.33 per share, with a total value of $492,660.00. Following the acquisition, the director owned 2,900 shares in the company, valued at $714,357. This trade represents a 222.22% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Mads Bodenhoff sold 3,000 shares of the firm's stock in a transaction on Tuesday, September 8th. The shares were sold at an average price of $270.19, for a total value of $810,570.00. Following the completion of the sale, the senior vice president directly owned 3,000 shares in the company, valued at approximately $810,570. This represents a 50.00% decrease in their position. The SEC filing for this sale provides additional information. 40.00% of the stock is owned by corporate insiders.

Institutional Trading of Ascendis Pharma A/S

Large investors have recently bought and sold shares of the business. Cetera Investment Advisers acquired a new position in Ascendis Pharma A/S during the second quarter worth about $552,000. Rhumbline Advisers boosted its stake in shares of Ascendis Pharma A/S by 4.0% in the 2nd quarter. Rhumbline Advisers now owns 1,441 shares of the biotechnology company's stock valued at $249,000 after purchasing an additional 55 shares in the last quarter. Daiwa Securities Group Inc. boosted its stake in shares of Ascendis Pharma A/S by 66.2% in the 2nd quarter. Daiwa Securities Group Inc. now owns 3,737 shares of the biotechnology company's stock valued at $645,000 after purchasing an additional 1,488 shares in the last quarter. Qube Research & Technologies Ltd grew its holdings in shares of Ascendis Pharma A/S by 83.4% during the 2nd quarter. Qube Research & Technologies Ltd now owns 201,044 shares of the biotechnology company's stock valued at $34,700,000 after purchasing an additional 91,412 shares during the last quarter. Finally, Squarepoint Ops LLC bought a new stake in shares of Ascendis Pharma A/S during the 2nd quarter valued at approximately $897,000.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S NASDAQ: ASND is a biopharmaceutical company focused on developing and commercializing therapies for rare diseases. The company uses its proprietary TransCon technology platform to design long-acting medicines intended to improve the effectiveness, convenience, and tolerability of established treatments.

Ascendis' marketed products include Skytrofa (lonapegsomatropin-tcgd), a long-acting growth hormone approved for the treatment of growth hormone deficiency in children, and Yorvipath (palopegteriparatide), a hormone replacement therapy for adults with hypoparathyroidism.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.